Becker's Healthcare September 16, 2021
Katie Adams

Hospitals participating in the 340B drug discount program price oncology drugs at an average of 3.8 times their 340B acquisition costs, according to a report the Community Oncology Alliance published Sept. 14.

The research team analyzed price transparency data for 340B hospitals and found that across 59 oncology drugs, the lowest median markup was 2.4 times the 340B acquisition cost (Adcetris), and the highest was 11 times (Epogen).

They also found 340B hospitals don’t decrease the prices they...

Today's Sponsors


Today's Sponsors

Crossover Health

Today's Sponsor

Institute for Healthcare Improvement

Topics: Biotechnology, Health System / Hospital, Pharma, Pharma / Biotech, Provider, Survey / Study, Trends
Most Older Patients Can Manage Drugs After Hospital Discharge, Study Finds
Nonprofit Drug Maker Civica Rx Eclipses 1,200 U.S. Hospital Members
Civica Rx to ship 8 critical drugs to member hospitals by year-end
Will Consumers Cross the Cost-and-Trust Chasm Between Prescription Drugs and Hospitals?